ABSTRACT OBJECTIVES This study sought to evaluate the impact on antiarrhythmic drug (AAD) initiation on the risk of readmission after catheter ablation for atrial fibrillation (AF) among patients not already treated with an AAD.
Revision-Clinical Modification
Noseworthy et al. Charlson/Deyo comorbidity index (7) was used to assess the patient's overall baseline comorbidity burden, using ICD-9-CM codes to identify the 17 conditions during the baseline period. CHADS 2 score was calculated for each patient with a possible total score of 0 to 6 points and grouped into 3 categories: 0-1, 2, or 3þ. The components of the CHADS 2 score were also defined using diagnoses coded within the 12-month baseline period before the index procedure. Table 1) . Participants in our cohort were 59.8 AE 11.7 years of age, 70.3% were male, and 74.7% were white. The most common comorbidities were congestive heart failure (27.6%), Noseworthy et al. In total, 519 patients filled a prescription for an AAD on the day of or the day following discharge after the ablation. The most common AADs used were amiodarone, sotalol, dronedarone, and flecainide ( Table 2 ).
There was a significant reduction (p < 0.01) in the hospital readmission among those treated with an AAD (Figure 1 ). In the univariate models (Table 3) There was no significant difference between groups in the number of emergency department visits within 90 days of ablation ( Table 6 ).
FIGURE 1 Readmission After Catheter Ablation
Freedom from readmission after catheter ablation for atrial fibrillation among patients with and without AAD treatment. Values are n or n (%).
AAD ¼ antiarrhythmic drug. 
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DISCUSSION
The major finding of this study is that, among patients not already on an AAD, initiation of an AAD at discharge following catheter ablation for AF is associated with a significant reduction in readmission.
This finding persists after statistical adjustment for key comorbid conditions and patient variables. However, unlike our study, most of these patients Table 3 .
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had been on an antiarrhythmic agent before the ablation (73% had been on flecainide, 47% on amiodarone, and 28% on dronedarone) so this was a study of AAD continuation/discontinuation rather than initiation. Furthermore, the AF recurrence rate in this study was 42% at 2 months, suggesting that this was a population with particularly recalcitrant AF. These data suggest that among patients with AAD-refractory AF, AAD continuation offers little benefit beyond the ablation itself.
It is important to emphasize that our study exam- STUDY LIMITATIONS. Like all claims-based observational studies, there is the potential for undercoding or overcoding, which can reduce the accuracy of diagnoses and outcomes. We cannot infer the physician's intent based solely on the prescribing pattern.
FIGURE 2 Readmission by Antiarrhythmic Drug
Freedom from readmission after catheter ablation for atrial fibrillation among patients treated with various antiarrhythmic drugs. 
